Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300

Lantern Pharma Inc.

Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.
No specific trial results or financial data disclosed in the 8-K filing itself.
Investors must review the presentation exhibit for detailed clinical updates.

item 7.01 item 9.01

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-026696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.